Clinical trials: Sirolimus, completed
Acute Myocardial Infarction
Everolimus Stent in Myocardial Infarction
Randomized trial to test the efficacy and safety of newer Drug Eluting Stent generation in patient with acute myocardial infarction treated with primary percutaneous coronary intervention (PCI)
- Trial name
- RaCES-MI (NCT01684982)
- Testing
- everolimus eluting stent, sirolimus eluting stent
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- San Giuseppe Moscati Hospital
Non-Hodgkin's Lymphomas
The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's Lymphomas
This study is an open label, multicenter study with two phases: Phase I is a dose escalation study of RAD001 in combination with one injection of Rituximab 375 mg/m² per week during 4 weeks (28 days) in patients CD20 positive…
- Trial name
- (RAD001-R) (NCT01567475)
- Testing
- Everolimus and rituximab
- Where
- 5 sites in France
- Volunteers
- 21 people
- Sponsor
- The Lymphoma Academic Research Organisation
Prostate Cancer Patients With Detectable PSA Following Prostatectomy
Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy
This is a Phase 1 dose escalation study of an investigational agent, everolimus, given in combination with standard radiation therapy, in prostate cancers with a rising PSA following a prostatectomy.
- Trial name
- NCT01548807
- Testing
- Everolimus (RAD001)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Renal Angiomyolipoma
Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.
The purpose of this study was to assess the safety and efficacy of everolimus (Afinitor®) in Chinese patients with renal angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC).
- Trial name
- NCT03525834
- Testing
- Everolimus
- Where
- 5 sites in China
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Aging
Effect of mTOR Inhibition and Other Metabolism Modulating Interventions on the Elderly
The ability to mount an effective immune response declines with age, leaving the elderly increasingly susceptible to infectious diseases and cancer.
- Trial name
- NCT02874924
- Testing
- Rapamycin
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Renal Cell Carcinoma
Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy
Study PIM4973g is a multicenter, international, open-label Phase II trial. Participants with metastatic renal cell carcinoma who have progressed on or after VEGF targeted therapy will be randomized in 1:1 to two groups either to…
- Trial name
- NCT01442090
- Testing
- Everolimus, GDC-0980
- Where
- 22 sites in United States, France and 3 more
- Volunteers
- 85 people
- Sponsor
- Genentech, Inc.
Leukemia, Lymphoma
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT01027000
- Testing
- rituximab, busulfan, cyclophosphamide
- Where
- 25 sites in United States
- Volunteers
- 68 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Hepatocellular Carcinoma, Liver Transplantation
Research and Application for New Clinical Diagnosis and Treatment System for HBV Related HCC Liver Transplantation
The study evaluated the protein expression levels of FK506-binding protein 12 (FKBP12) in hepatocellular carcinoma (HCC) and paracancerous tissues using immunohistochemistry (IHC).
- Conditions
- Hepatocellular Carcinoma, Liver Transplantation, Prognosis
- Trial name
- NCT06409507
- Testing
- FKBP12 expression
- Volunteers
- 178 people
- Sponsor
- First People's Hospital of Hangzhou
Drug-eluting Stent, Coronary Artery Disease
Genoss DES in Patients With a High Risk of Ischemic Events (GENTLE Registry)
This is a prospective cohort study to evaluate the long-term effect and safety of Genoss drug-eluting stents (DES) in patients with coronary artery disease with high ischemic features.
- Trial name
- NCT05448625
- Testing
- Genoss DES
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Yonsei University
Germ Cell Tumor
Everolimus in Refractory Testicular Germ Cell Cancer
Everolimus in refractory testicular germ cell cancer. Everolimus 10 mg /day/ is administered to the patient until progression, unacceptable toxicity, complete response or inability of the subject to comply with study…
- Trial name
- NCT01466231
- Testing
- Everolimus
- Where
- Slovakia
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute, Slovakia
Coronary Artery Disease, Drug-eluting Stents
Safety and Efficacy of the Ultimaster Stent
Durable polymer was considered to be the cause of a chronic inflammatory response that leadas to impaired endothelialization of the stent strut and subsequently increases the risk of stent thrombosis.
- Trial name
- NCT05677711
- Testing
- ultimaster
- Where
- South Korea
- Volunteers
- 204 people
- Sponsor
- Yonsei University
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma
This phase I/II trial studies the side effects and best dose of temsirolimus when given together with perifosine and to see how well it works in treating patients with recurrent or progressive malignant glioma.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma
- Trial name
- NCT01051557
- Testing
- Laboratory Biomarker Analysis, Perifosine, Temsirolimus
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Urothelial Carcinoma, Bladder Cancer
Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
Background: Advanced urothelial cancer has no cure. But only a few chemotherapy drugs have been tested for it. The Co-eXpression ExtrapolatioN (COXEN) model predicts if cells respond to treatment.
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms
- Trial name
- NCT02788201
- Testing
- 75 approved agents, COXEN
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Pharmacokinetics, Drug Interactions
Pharmacokinetic Drug Interaction Between Ezetimibe and Sirolimus After Single Dose Administration in Healthy Subjects
The purpose of this study is to confirm a significant influence of ezetimibe and sirolimus on each others pharmacokinetics
- Conditions
- Pharmacokinetics, Drug Interactions, Hypercholesterolemia, Immunosuppression
- Trial name
- NCT00621101
- Testing
- 1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany, 1 tablet Rapamune(R) (sirolimus), Wyeth Pharma, Germany, 1 tablet Ezetrol(R) + 1 tablet Rapamune(R)
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Medicine Greifswald
Liver Transplantation
Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant
This two-arm study will assess the efficacy and safety of a long-term calcineurin inhibitor-free maintenance regimen with CellCept and sirolimus in recipients of an orthotropic liver transplant.
- Trial name
- NCT00118742
- Testing
- mycophenolate mofetil [CellCept], Tacrolimus, Cyclosporine
- Where
- 46 sites in United States, Canada
- Volunteers
- 293 people
- Sponsor
- Hoffmann-La Roche
Myeloproliferative Disorders, Leukemia
Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant
RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00305682
- Testing
- anti-thymocyte globulin, cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 295 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Intracranial Arteriosclerosis, Stroke (CVA) or TIA
Evaluating the Safety and Efficacy of the Maurora® DES in ICAS
The purpose of the RCT trial is to evaluate whether implantation of drug-eluting stent (DES) is more efficacious than bare metal stent (BMS) in prevention of in-stent restenosis (ISR) and improvement of outcomes for symptomatic…
- Trial name
- Maurora ICAS (NCT05719883)
- Testing
- Maurora® Sirolimus Eluting Stent System, APOLLO™ Intracranial Stent System
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Beijing Tiantan Hospital
Major Depressive Disorder
Open-Label of SPN-820 in Adults With Major Depressive Disorder
This study will evaluate of the efficacy and safety of SPN-820 in Adults With Major Depressive Disorder (MDD)
- Trial name
- NCT06235905
- Testing
- NV-5138
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Navitor Pharmaceuticals, Inc.
Lung Cancer
Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Gefitinib and everolimus may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Giving gefitinib together with everolimus may kill more tumor cells.
- Trial name
- NCT00096486
- Testing
- everolimus, gefitinib
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Kidney Transplantation, Renal Transplantation
Tolerance by Engaging Antigen During Cellular Homeostasis
Anti-rejection medicines, also known as immunosuppressive drugs, are prescribed to organ transplant recipients to prevent rejection of the new organ.
- Conditions
- Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient
- Trial name
- TEACH (NCT03504241)
- Testing
- Donor-derived Mesenchymal Stromal Cells, alemtuzumab, belatacept
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.